Penumbra (PEN) Capital Expenditures Growth (1y) (2015 - 2026)
Penumbra (PEN) Capital Expenditures Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.54 Bn | 176.25 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.93 Bn | 126.05 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.84 Bn | 99.62 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.42 Bn | 66.96 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 47.32 Bn | 43.65 Bn | 1.29 Bn | 15.89% |
| 6 | GE HealthCare Technologies | 28.46 Bn | 26.18 Bn | 1.98 Bn | 106.98% |
| 7 | Dexcom | 28.46 Bn | 27.34 Bn | 750.30 Mn | -11.95% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.55 Bn | 22.42 Bn | 2.07 Bn | -47.73% |
| 10 | Penumbra | 12.56 Bn | 11.94 Bn | 253.41 Mn | 582.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 582.05% |
| Dec 31, 2025 | -30.29% |
| Sep 30, 2025 | -604.49% |
| Jun 30, 2025 | 502.27% |
| Mar 31, 2025 | -70.35% |
| Dec 31, 2024 | 5,875.27% |
| Sep 30, 2024 | 2,924.35% |
| Jun 30, 2024 | 1,549.20% |
| Mar 31, 2024 | 227.01% |
| Dec 31, 2023 | 99.31% |
| Sep 30, 2023 | -103.04% |
| Jun 30, 2023 | -107.06% |
| Mar 31, 2023 | -64.07% |
| Dec 31, 2022 | -182.27% |
| Sep 30, 2022 | 143.87% |
| Jun 30, 2022 | 352.48% |
| Mar 31, 2022 | 24.20% |
| Dec 31, 2021 | 14,955.45% |
| Sep 30, 2021 | 116.98% |
| Jun 30, 2021 | -126.12% |